Emil Kuriakose Sells 942 Shares of Terns Pharmaceuticals (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) insider Emil Kuriakose sold 942 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $52.75, for a total transaction of $49,690.50. Following the sale, the insider directly owned 105,673 shares in the company, valued at $5,574,250.75. The trade was a 0.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Emil Kuriakose also recently made the following trade(s):

• On Friday, January 2nd, Emil Kuriakose sold 1,155 shares of Terns Pharmaceuticals stock. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35.

Terns Pharmaceuticals Stock Down 0.1%

Shares of TERN stock traded down $0.07 during trading hours on Thursday, hitting $52.72. 10,849,699 shares of the company’s stock traded hands, compared to its average volume of 4,369,557. The stock’s fifty day simple moving average is $42.25 and its two-hundred day simple moving average is $30.16. Terns Pharmaceuticals, Inc. has a 12-month low of $1.87 and a 12-month high of $53.19. The stock has a market cap of $6.08 billion, a price-to-earnings ratio of -51.18 and a beta of -0.37.

Terns Pharmaceuticals (NASDAQ:TERN) last posted its quarterly earnings data on Thursday, April 2nd. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06. On average, equities analysts forecast that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Terns Pharmaceuticals

A number of hedge funds have recently bought and sold shares of TERN. Commodore Capital LP bought a new position in Terns Pharmaceuticals during the third quarter valued at approximately $42,807,000. Vestal Point Capital LP bought a new stake in Terns Pharmaceuticals in the 4th quarter worth approximately $181,800,000. Avoro Capital Advisors LLC purchased a new stake in Terns Pharmaceuticals during the 4th quarter valued at $175,740,000. Janus Henderson Group PLC bought a new position in shares of Terns Pharmaceuticals during the 4th quarter valued at $136,496,000. Finally, Capitolis Liquid Global Markets LLC purchased a new position in shares of Terns Pharmaceuticals in the 4th quarter worth $123,026,000. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on TERN shares. HC Wainwright reiterated a “neutral” rating and issued a $53.00 price target (down from $60.00) on shares of Terns Pharmaceuticals in a research note on Wednesday, March 25th. Citizens Jmp cut shares of Terns Pharmaceuticals from a “market outperform” rating to a “hold” rating in a report on Thursday, March 26th. Wall Street Zen downgraded shares of Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Barclays reiterated an “equal weight” rating and set a $53.00 price target (down from $56.00) on shares of Terns Pharmaceuticals in a report on Monday. Finally, BMO Capital Markets lowered shares of Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Terns Pharmaceuticals presently has an average rating of “Hold” and an average price target of $56.30.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.